- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of psychiatric medications closely associated with the risk and progression of ALS: JAMA

A new study published in the Journal of American Medical Association showed that an increased risk of amyotrophic lateral sclerosis (ALS) was linked to prediagnostic use of sedatives, antidepressants, hypnotics, and anxiolytics.
While a number of studies have indicated that people with a history of mental illnesses are more likely to be diagnosed with ALS, there is little and conflicting evidence linking the use of popular psychiatric drugs to ALS. Thus, the purpose of this study was to investigate if the risk and course of ALS are related to the prescribed use of popular psychiatric drugs, such as antidepressants, hypnotics and sedatives, and anxiolytics.
Based on the Swedish Motor Neuron Disease Quality Registry, this nationwide register-based case-control study was carried out in Sweden among all patients diagnosed with ALS between January 1, 2015, and July 1, 2023. These patients were matched for age and sex with up to five people who did not have ALS, as well as their spouses and full siblings.
Following diagnosis, ALS patients were monitored for a median (IQR) of 1.33 (0.64-2.37) years. Conditional logistic regression models were used to compare patients with ALS to population or relative control participants in order to evaluate the probability of ALS diagnosis linked to prediagnostic prescription usage of popular mental drugs. Following diagnosis, ALS patients were monitored to see whether prediagnostic prescription usage of popular mental drugs was associated with the advancement of the disease.
In a research study with 1,057 ALS cases and 5,281 controls (mean age 67.5 years; 53.1% male), using psychiatric drugs before being diagnosed with ALS was associated with a higher chance of getting the condition. In particular, the strongest correlation (OR 6.10) was seen for hypnotic/sedative usage during the first year, followed by anxiolytic use (OR 1.60) and antidepressant use (OR 1.21) across longer time periods.
For all 3 medication groups, the increased risk remained even after excluding prescriptions written in the year before the diagnosis. With the exception of hypnotics and sedatives, similar correlations were found when comparing with relatives, allaying worries regarding hereditary influences. Additionally, ALS patients who had previously used antidepressants or anxiolytics had lower survival times.
Overall, the use of antidepressants, hypnotics and sedatives, or anxiolytics was linked to an increased chance of receiving an ALS diagnosis in the future. Among ALS patients, prediagnostic usage of several of these drugs was likewise linked to a worse survival rate and a quicker functional deterioration.
Reference:
Chourpiliadis, C., Lovik, A., Ingre, C., Press, R., Samuelsson, K., Valdimarsdottir, U., & Fang, F. (2025). Use of common psychiatric medications and risk and prognosis of amyotrophic lateral sclerosis. JAMA Network Open, 8(6), e2514437. https://doi.org/10.1001/jamanetworkopen.2025.14437
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751